ImmunityBio Q1 2026 Financial and Operational Update: Key Highlights for Investors
ImmunityBio Reports Record Q1 2026 Revenue Growth and Expanding Global Footprint
Summary of Key Financial and Operational Results
- Record Q1 2026 net product revenue: ImmunityBio reported preliminary net product revenue of approximately \$44.2 million for Q1 2026, marking a substantial 168% year-over-year increase compared to Q1 2025.
- Consistent quarter-over-quarter growth: Since the launch of ANKTIVA®, the company has seen sustained revenue growth, including a 15% sequential increase from Q4 2025’s \$38.3 million.
- Impressive full-year 2025 performance: The company achieved net product revenue of \$113 million in 2025, representing a 700% increase over the full-year 2024.
- Strong cash position: ImmunityBio ended Q1 2026 with approximately \$380.9 million in cash, cash equivalents, and marketable securities.
- Global regulatory expansion: ANKTIVA is now approved or authorized in five regulatory jurisdictions, covering about 34 countries.
- Clinical milestones: The pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with the Independent Data Monitoring Committee (IDMC) confirming adequate statistical power. A supplemental BLA submission is on track for 2026.
- NCCN Guidelines Update: In March 2026, the NCCN Clinical Practice Guidelines were updated to include ANKTIVA as BCG for BCG-unresponsive NMIBC with papillary-only disease (Category 2A).
Operational Highlights and Leadership Comments
ImmunityBio continues to demonstrate strong momentum in the commercial adoption of ANKTIVA, especially in the BCG-unresponsive NMIBC CIS setting. According to company leadership, feedback from treating urologists remains consistently positive. The full enrollment of pivotal clinical trials and IDMC confirmation of statistical power further solidify ANKTIVA’s clinical profile and support ongoing regulatory submissions.
Richard Adcock, President and CEO, emphasized the company’s focus on scaling in the U.S. and expanding into more global markets following the robust growth in 2025. Dr. Patrick Soon-Shiong, Founder and Executive Chairman, noted sustained momentum, positive feedback from physicians, and growing investigator participation across clinical programs, supporting ImmunityBio’s broader pipeline development. The company remains committed to advancing new treatment options for bladder cancer and other indications.
Strategic and Pipeline Developments
- Cancer BioShield™ Platform: At the core of ImmunityBio’s strategy is its proprietary Cancer BioShield platform, built around ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist designed to stimulate critical lymphocytes such as NK cells, cytotoxic T cells, and memory T cells.
- Diversified pipeline: The platform is complemented by adenovirus-vectored vaccines, allogeneic and autologous NK-cell therapies, and additional immunomodulators aimed at supporting durable immune responses and potentially reducing dependence on high-dose chemotherapy and radiation.
- Expanded clinical trial activity: Strong enrollment and investigator participation is supporting pipeline advancement across multiple solid and liquid tumor types.
Potential Shareholder Impacts and Price-Sensitive Information
- Significant revenue growth: The sharp increase in net product revenue and the company’s robust cash position may positively influence investor sentiment and potentially impact share price.
- Regulatory approvals and guideline inclusion: ANKTIVA’s approval in more jurisdictions and inclusion in NCCN guidelines are likely to drive further adoption, supporting future revenue growth.
- Pivotal clinical trial progress: Full enrollment and IDMC confirmation of statistical power for key trials may accelerate regulatory pathways and product expansion.
- Pipeline development: The company’s ongoing commitment to advancing its immunotherapy portfolio and expanding indications may attract investor interest.
- Forward-looking risks: The company cautions that preliminary financial results may differ from final figures, and numerous risks (clinical trial outcomes, regulatory acceptance, manufacturing scale-up, and financing needs) could affect future performance.
Forward-Looking Statements and Risk Factors
Investors should note that all financial results are preliminary and subject to final adjustments. The company faces risks related to clinical trial outcomes, regulatory reviews, funding, manufacturing, commercialization, and intellectual property protection. These risks are detailed in ImmunityBio’s recent SEC filings, including its Annual Report on Form 10-K.
Investor Contacts
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as described in ImmunityBio’s SEC filings. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.
View ImmunityBio, Inc. Historical chart here
